Abstract
In the last twenty years there has been significant progress in the treatment of inflammatory bowel disease , Crohn's disease and ulcerative colitis , which was recorded only in the conservative therapy , but also in surgical treatment. For patients with ulcerative colitis is the basis therapy aminosalicylates administration orally or topically , alone or in combination.
At least 30-40 % of the patients in the course of the disease requires more aggressive treatments involving the application of corticosteroids , immunosuppressants , and biological therapy. The main use of biological therapy in patients who do not respond to treatment with glucocorticoids or are dependent on it , and in patients who are profiting established immunosuppressive therapy.
Infliximab was introduced into clinical practice in the treatment of ulcerative colitis in 2006 and with it also the largest and longest experience. Its short term effectiveness in clinical practice is very high with a positive response in 80-90 % of patients.
In addition to the innovation and introduction of new drugs of biological specimens into the future considering the use of intensive treatment strategy based on selecting high-risk patients with poor prognosis , enabling the initiation of aggressive treatment even before any structural changes in the intestine. The second approach , which should improve the results of long-term treatment is increased and more accurate monitoring inflammatory activity